Alternative Medications to Replace Metformin in Patients with Intolerance

First-Line Alternatives Based on Patient Profile

The American Diabetes Association recommends initial therapy with sulfonylureas, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, or basal insulin in patients with metformin intolerance or contraindications, based on patient-specific cardiovascular risk, comorbidities, and drug characteristics 1
For patients with established cardiovascular disease or high cardiovascular risk, the American Diabetes Association prioritizes GLP-1 receptor agonists or SGLT2 inhibitors due to their demonstrated cardiovascular risk reduction in outcomes trials 2, 3
The American Heart Association recommends SGLT2 inhibitors as early therapy in type 2 diabetes with established kidney disease or heart failure, as they provide renal and cardiac protection 3, 4

Sulfonylureas reduce HbA1c by 1.0-1.5%, with a major advantage of low cost and well-established efficacy, but have a major disadvantage of risk of hypoglycemia and weight gain 6, 7
Thiazolidinediones reduce HbA1c by 0.7-1.0%, with advantages of not causing hypoglycemia when used alone and improving insulin sensitivity, but have disadvantages of weight gain, edema, and increased risk of bone fractures in postmenopausal women 6, 7
DPP-4 inhibitors reduce HbA1c by approximately 0.7-1.0%, with advantages of being weight neutral, having a low hypoglycemia risk, and once-daily dosing, but have disadvantages of being less potent than other options and having a higher cost 1, 2, 3, 4
SGLT2 inhibitors reduce HbA1c by approximately 0.7-1.0%, with advantages of weight loss, very low hypoglycemia risk, and cardiovascular and renal benefits 3, 4
GLP-1 receptor agonists reduce HbA1c by approximately 1.0-1.1%, with advantages of weight loss, low hypoglycemia risk, and cardiovascular benefits, but have disadvantages of being injectable, having gastrointestinal side effects, and being high cost 1, 2

The American Diabetes Association recommends assessing baseline HbA1c and considering insulin therapy if HbA1c ≥10% or blood glucose ≥300 mg/dL with symptoms, and considering dual therapy if HbA1c ≥9% 2, 3
The American Heart Association recommends evaluating cardiovascular and renal status and prioritizing GLP-1 receptor agonists or SGLT2 inhibitors if established ASCVD, high CV risk, CKD, or heart failure are present 2, 3, 4

The American Diabetes Association recommends reassessing HbA1c every 3 months until glycemic target is achieved, and adding a second agent from a different class if monotherapy fails to achieve target after 3 months 2, 3, 4